- 3.4Impact Factor
- 9.9CiteScore
- 20 daysTime to First Decision
Vaccines, Volume 11, Issue 3
March 2023 - 221 articles
Cover Story: Humoral SARS-CoV-2 immunity up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous vector–vector vs. heterologous vector–mRNA), the influence of vaccination side effects and the infection rate in German healthcare workers were examined. We enrolled 103 individuals vaccinated against SARS-CoV-2. All individuals demonstrated a humoral immune response not decreasing below the positivity cutoff. The incidence of vaccine breakthrough in a highly exposed cohort was 60.3%. Long-term humoral immunity was observed, indicating the superiority of a heterologous mRNA-/vector-based combination compared to pure vector-based vaccination. A correlation between the antibody titer and vaccination side effects was not observed. Despite the high prevalence of vaccine breakthroughs, these only occurred when more infectious variants associated with milder courses were present. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles
There are no articles in this issue yet.
Get Alerted
Add your email address to receive forthcoming issues of this journal.
Vaccines - ISSN 2076-393X